Precise diagnosis and targeted treatments improve patient outcomes. Scailyte’s pioneering technology integrates multimodal single cell and clinical data to identify novel disease signatures.
Supported by
Our pillars
High-quality biomedical data sets
Targeted, trustworthy and sensitive algorithms
.
Bold industrialization and adoption
Scailyte is an AI enabled company transforming precision medicine for the medical R&D community. Scailyte is a multi-disciplinary diverse team, science and solution partner.
ScaiVisionTM, our proprietary and best-in-class biomarker discovery platform, can expose precise novel molecular signatures with deep cellular insights.
From discovery to next generation clinical applications
Study Design
Wet/Dry lab setup and experimental design
Data analysis workflow
Data Acquisition
Identification and optimization of suitable single-cell method(s)
Sample preparation and processing
Biomedical insights
Single-cell data allows for unprecedented insight into health and disease, opening new avenues for diagnostics and therapeutics of complex diseases areas like oncology and women’s health.
Making groundbreaking discoveries and bringing innovation into clinical practice requires strong collaborations and joint-ventures.
Scailyte unlocks novel disease insights for medical researchers, accelerating late stage medical R&D and increasing the chance of successful drug development. We are looking for partners to step up and passionately pursue our science to address unmet patient needs.
Our investors
Recent News
ScaiVision® performs best-in-class at sample class prediction!
ScaiVision® v1.0.0 was released internally and benchmarked in a massive experiment, outperforming a
Recent News
Scailyte participates @ swissnex san francisco DEMO DAY!
Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day
Recent News
Scailyte Q3 2020 Update
Q3 2020 update on Scailyte's progress towards its mission to save millions of lives.
Recent News
ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.
As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus,
Recent News
Recent News
Interview with Scailyte’s CEO Peter Nestorov
In the interview done by Venturelab, Peter talks about the challenges of an entrepreneur. As the CEO
Recent News
Interview with Scailyte Founder Prof. Dr. Manfred Claassen
In an interview with Investiere our founder and scientific advisor Prof. Dr. Manfred Claassen descri
Recent News
Scailyte: simplifying difficult diagnoses
Making a diagnosis can be a tricky endeavour. For instance, diagnosing skin T-cell lymphoma, a rare
Recent News
ScaiVision® performs best-in-class at sample class prediction!
ScaiVision® v1.0.0 was released internally and benchmarked in a massive experiment, outperforming a
Scailyte participates @ swissnex san francisco DEMO DAY!
Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day
Recent News
Scailyte Q3 2020 Update
Q3 2020 update on Scailyte's progress towards its mission to save millions of lives.
ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.
As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus,
Recent News
Interview with Scailyte’s CEO Peter Nestorov
In the interview done by Venturelab, Peter talks about the challenges of an entrepreneur. As the CEO
Recent News
Interview with Scailyte Founder Prof. Dr. Manfred Claassen
In an interview with Investiere our founder and scientific advisor Prof. Dr. Manfred Claassen descri
Scailyte: simplifying difficult diagnoses
Making a diagnosis can be a tricky endeavour. For instance, diagnosing skin T-cell lymphoma, a rare